Therapeutic Vaccination for HPV-Mediated Cancers.

IF 0.4 Q4 OTORHINOLARYNGOLOGY

Current Otorhinolaryngology Reports Pub Date : 2023-01-01 DOI:10.1007/s40136-023-00443-8

Flora Yan, Lindsay G Cowell, Anna Tomkies, Andrew T Day

{"title":"Therapeutic Vaccination for HPV-Mediated Cancers.","authors":"Flora Yan, Lindsay G Cowell, Anna Tomkies, Andrew T Day","doi":"10.1007/s40136-023-00443-8","DOIUrl":null,"url":null,"abstract":"Purpose of review: The goal of this narrative review is to educate clinicians regarding the foundational concepts, efficacy, and future directions of therapeutic vaccines for human papillomavirus (HPV)-mediated cancers.Recent findings: Therapeutic HPV vaccines deliver tumor antigens to stimulate an immune response to eliminate tumor cells. Vaccine antigen delivery platforms are diverse and include DNA, RNA, peptides, proteins, viral vectors, microbial vectors, and antigen-presenting cells. Randomized, controlled trials have demonstrated that therapeutic HPV vaccines are efficacious in patients with cervical intraepithelial neoplasia. In patients with HPV-mediated malignancies, evidence of efficacy is limited. However, numerous ongoing studies evaluating updated therapeutic HPV vaccines in combination with immune checkpoint inhibition and other therapies exhibit significant promise.Summary: Therapeutic vaccines for HPV-mediated malignancies retain a strong biological rationale, despite their limited efficacy to date. Investigators anticipate they will be most effectively used in combination with other regimens, such as immune checkpoint inhibition.","PeriodicalId":36165,"journal":{"name":"Current Otorhinolaryngology Reports","volume":"11 1","pages":"44-61"},"PeriodicalIF":0.4000,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890440/pdf/","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Otorhinolaryngology Reports","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s40136-023-00443-8","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OTORHINOLARYNGOLOGY","Score":null,"Total":0}

引用次数: 4

Abstract

Purpose of review: The goal of this narrative review is to educate clinicians regarding the foundational concepts, efficacy, and future directions of therapeutic vaccines for human papillomavirus (HPV)-mediated cancers.

Recent findings: Therapeutic HPV vaccines deliver tumor antigens to stimulate an immune response to eliminate tumor cells. Vaccine antigen delivery platforms are diverse and include DNA, RNA, peptides, proteins, viral vectors, microbial vectors, and antigen-presenting cells. Randomized, controlled trials have demonstrated that therapeutic HPV vaccines are efficacious in patients with cervical intraepithelial neoplasia. In patients with HPV-mediated malignancies, evidence of efficacy is limited. However, numerous ongoing studies evaluating updated therapeutic HPV vaccines in combination with immune checkpoint inhibition and other therapies exhibit significant promise.

Summary: Therapeutic vaccines for HPV-mediated malignancies retain a strong biological rationale, despite their limited efficacy to date. Investigators anticipate they will be most effectively used in combination with other regimens, such as immune checkpoint inhibition.

查看原文本刊更多论文

hpv介导的癌症的治疗性疫苗接种。

综述的目的:这篇叙述性综述的目的是教育临床医生关于人乳头瘤病毒(HPV)介导的癌症治疗性疫苗的基本概念、疗效和未来方向。最近的发现:治疗性HPV疫苗提供肿瘤抗原，刺激免疫反应，消除肿瘤细胞。疫苗抗原递送平台多种多样，包括DNA、RNA、多肽、蛋白质、病毒载体、微生物载体和抗原呈递细胞。随机对照试验表明，治疗性HPV疫苗对宫颈上皮内瘤变患者有效。在hpv介导的恶性肿瘤患者中，有效性的证据有限。然而，许多正在进行的研究评估了更新的治疗性HPV疫苗与免疫检查点抑制和其他疗法的结合，显示出重大的希望。摘要:hpv介导的恶性肿瘤的治疗性疫苗保留了强有力的生物学依据，尽管迄今为止它们的疗效有限。研究人员预计，它们将最有效地与其他方案联合使用，如免疫检查点抑制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Current Otorhinolaryngology Reports Medicine-Surgery

CiteScore

1.00

自引率

16.70%

发文量

期刊介绍： This journal aims to offer expert review articles on the most significant recent developments in the field of otorhinolaryngology. By providing clear, insightful, balanced contributions, the journal intends to serve all those involved in the diagnosis and treatment of ear, nose, throat, and head and neck disorders. We accomplish this aim by appointing international authorities to serve as Section Editors in key subject areas across the field. Section Editors select topics for which leading experts contribute comprehensive review articles that emphasize new developments and recently published papers of major importance, highlighted by annotated reference lists. An Editorial Board of more than 20 internationally diverse members reviews the annual table of contents, ensures that topics include emerging research, and suggests topics of special importance to their country/region. Topics covered may include chronic rhinosinusitis; implantable devices; neurolaryngology; otolaryngic allergy; robotic surgery; sleep apnea; skull base surgery; thyroid surgery; and quality and outcomes.